VERASTEM INC (VSTM)       0.85  -0.02 (-1.97%)

0.85  -0.02 (-1.97%)

US92337C1045 - Common Stock - After market: 0.87 +0.02 (+2.35%)

VERASTEM INC0.85

NASDAQ:VSTM (9/30/2022, 7:00:02 PM)-0.02 (-1.97%)

After market: 0.87 +0.02 (+2.35%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 08-08 2022-08-08/bmo Earnings (Next) 11-02 2022-11-02
Ins Owners 1.71% Inst Owners 58.81%
Market Cap 159.64M Shares 187.81M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 82
IPO 11-08 2011-11-08

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

VSTM Daily chart

Company Profile

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2011-11-08. The firm's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition. Its advanced product candidates, VS-6766 and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, uveal melanoma, and endometrial cancer. VS-6766 is an orally available small molecule RAF/MEK clamp. VS-6766 is a dual RAF/MEK clamp that blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2) that is being evaluated as a potential combination therapy for various solid tumors.

Company Info

VERASTEM INC

117 Kendrick St Ste 500

Cambridge MASSACHUSETTS 02494

P: 16172529300.0

CEO: Brian M. Stuglik

Employees: 48

Website: http://www.verastem.com/

VSTM Twits

Here you can normally see the latest stock twits on VSTM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example